Patent Foramen Ovale and Stroke

Area of Science:

• Cardiology
• Neurology
• Vascular Medicine

Background:

• A patent foramen ovale (PFO) is a common cardiac anomaly associated with an increased risk of ischemic stroke.
• The presumed mechanism involves paradoxical embolism, where venous clots travel through the PFO to the systemic circulation.
• Current primary stroke prevention data for PFO patients is lacking, and no therapy is recommended for asymptomatic individuals.

Purpose of the Study:

• To review the current understanding of patent foramen ovale (PFO) and its association with ischemic stroke.
• To evaluate the existing treatment options for preventing recurrent stroke in patients with PFO.
• To identify knowledge gaps and the need for further research, particularly randomized trials comparing PFO closure with medical management.

Main Methods:

• Review of observational data from prospective and retrospective trials.
• Analysis of findings from the Patent Foramen Ovale in Cryptogenic Stroke Study.
• Discussion of current treatment modalities including surgical closure, percutaneous device closure, anticoagulants, and antiplatelet agents.

Main Results:

• Observational studies suggest a link between PFO and ischemic stroke risk, likely due to paradoxical embolism.
• The Patent Foramen Ovale in Cryptogenic Stroke Study found antiplatelet and anticoagulant therapies to be equally effective in preventing recurrent adverse events.
• No definitive randomized trials have compared PFO closure (surgical or percutaneous) with medical therapy.

Conclusions:

• While PFO is associated with stroke risk, primary prevention strategies are undefined.
• Medical therapies (anticoagulants and antiplatelet agents) offer comparable benefits for secondary prevention in PFO patients.
• The superiority of PFO closure over medical management for recurrent stroke prevention remains unproven and requires further investigation through randomized controlled trials.